⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2487140 | 1.00 | — | — | |
| SCHEMBL29035006 | 0.80 | — | — | |
| SCHEMBL2497821 | 0.79 | — | — | |
| SCHEMBL21409026 | 0.79 | — | — | |
| SCHEMBL376992 | 0.79 | — | — | |
| SCHEMBL2224543 | 0.79 | — | — | |
| SCHEMBL5123125 | 0.78 | — | — | |
| SCHEMBL9637164 | 0.78 | — | — | |
| SCHEMBL7298166 | 0.77 | — | — | |
| SCHEMBL3594415 | 0.77 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3533797-B1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2023-12-20 | — | — | EP | disclosed |
| EP-3559007-B1 | SULFONAMIDE COMPOUNDS HAVING TNAP INHIBITORY ACTIVITY | DAIICHI SANKYO CO LTD (JP) | 2023-08-16 | — | — | EP | disclosed |
| CN-110167946-B | Sulfonamide compounds having TNAP inhibitory activity | 第一三共株式会社 | 2022-04-08 | — | — | CN | disclosed |
| US-11274100-B2 | EP300/CREBBP inhibitor | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2022-03-15 | — | — | US | disclosed |
| US-11149023-B2 | Substituted triazole derivatives and uses thereof | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2021-10-19 | — | — | US | disclosed |
| US-11046710-B2 | Sulfonamide compounds | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2021-06-29 | — | — | US | disclosed |
| US-20210171520-A1 | EP300/CREBBP INHIBITOR | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2021-06-10 | — | — | US | disclosed |
| US-11014939-B2 | — | — | 2021-05-25 | — | — | US | disclosed |
| US-20200255402-A1 | SUBSTITUTED TRIAZOLE DERIVATIVES AND USES THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2020-08-13 | — | — | US | disclosed |
| EP-3643703-A1 | EP300/CREBBP INHIBITOR | Daiichi Sankyo Co., Ltd. (JP) | 2020-04-29 | — | — | EP | disclosed |
| US-7462641-B2 | (2S,4S)-4-fluoro-1-[4-fluoro-beta-(4-fluorophenyl)-L-phenylalanyl]-2-pyrrolidinecarbonitrile p-toluenesulfonic acid salt and anhydrous crystalline forms thereof | SMITHKLINE BEECHAM CORPORATION (US) | 2008-12-09 | — | — | US | disclosed |
| EP-1654226-B1 | (2S,4S)-4-FLUORO-1- 4-FLUORO-BETA-(4-FLUOROPHENYL)-L-PHENYLALANYL -2-PYRROLIDINECARBONITRILE P-TOLUENESULFONIC ACID SALT AND ANHYDROUS CRYSTALLINE FORMS THEREOF | SMITHKLINE BEECHAM CORP (US) | 2008-10-22 | — | — | EP | disclosed |
| EP-1406872-B1 | DIPEPTIDYL PEPTIDASE INHIBITORS FOR THE TREATMENT OF DIABETES | MERCK & CO INC (US) | 2007-12-19 | — | — | EP | disclosed |
| US-20070066677-A1 | (2S,4s)-4-fluoro-1-[4-fluoro-beta-(4-fluorophenyl)-I-phenylalanyl]-2-pyrrolidinecarbonitrile p-toluenesulfonic acid salt and anhydrous crystalline forms thereof | SMITHKLINE BEECHAM CORPORATION | 2007-03-22 | — | — | US | disclosed |
| US-20060276449-A1 | 1,3-Dihydro-2h-indol-2-one derivative | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2006-12-07 | — | — | US | disclosed |
| US-7098239-B2 | Dipeptidyl peptidase inhibitors for the treatment of diabetes | MERCK & CO., INC (US) | 2006-08-29 | — | — | US | disclosed |
| EP-1659121-A1 | 1,3-DIHYDRO-2H-INDOL-2-ONE DERIVATIVE | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2006-05-24 | — | — | EP | disclosed |
| EP-1654226-A1 | (2S,4S)-4-FLUORO-1- 4-FLUORO-BETA-(4-FLUOROPHENYL)-L-PHENYLALANYL -2-PYRROLIDINECARBONITRILE P-TOLUENESULFONIC ACID SALT AND ANHYDROUS CRYSTALLINE FORMS THEREOF | SmithKline Beecham Corporation (US) | 2006-05-10 | — | — | EP | disclosed |
| WO-2005009956-A1 | (2S,4S)-4-FLUORO-1-[4-FLUORO-BETA-(4-FLUOROPHENYL)-L-PHENYLALANYL]-2-PYRROLIDINECARBONITRILE P-TOLUENESULFONIC ACID SALT AND ANHYDROUS CRYSTALLINE FORMS THEREOF | SMITHKLINE BEECHAM CORPORATION (US) | 2005-02-03 | — | — | WO | disclosed |
| US-20040176428-A1 | Dipeptidyl peptidase inhibitors for the treatment of diabetes | MERCK SHARP & DOHME CORP. | 2004-09-09 | — | — | US | disclosed |